[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate]

Encephale. 2020 Jun;46(3S):S126-S127. doi: 10.1016/j.encep.2020.05.009. Epub 2020 May 21.
[Article in French]
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Anticonvulsants / administration & dosage
  • Anticonvulsants / therapeutic use
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Betacoronavirus*
  • COVID-19
  • Clozapine / administration & dosage
  • Clozapine / adverse effects
  • Clozapine / therapeutic use*
  • Coronavirus Infections / complications*
  • Delayed-Action Preparations
  • Drug Resistance
  • Drug Therapy, Combination
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Lithium Carbonate / administration & dosage
  • Lithium Carbonate / therapeutic use
  • Male
  • Middle Aged
  • Paliperidone Palmitate / administration & dosage
  • Paliperidone Palmitate / therapeutic use*
  • Pandemics*
  • Pneumonia, Viral / complications*
  • Psychotic Disorders / drug therapy*
  • SARS-CoV-2
  • Sialorrhea / chemically induced
  • Treatment Outcome
  • Valproic Acid / administration & dosage
  • Valproic Acid / therapeutic use

Substances

  • Anticonvulsants
  • Antipsychotic Agents
  • Delayed-Action Preparations
  • Immunologic Factors
  • Lithium Carbonate
  • Valproic Acid
  • Clozapine
  • Paliperidone Palmitate